Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet

Flavio Vincenti; Klemens Budde; Josep Grinyo; Lionel Rostaing; Allan D. Kirk; Christian P. Larsen

doi:10.1016/j.ajt.2023.05.033

Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet

Flavio Vincenti^*, Klemens Budde, Josep Grinyo, Lionel Rostaing, Allan D. Kirk, Christian P. Larsen

^*Corresponding author for this work

Research output: Contribution to journal › Editorial

4 Scopus citations

Original language	English
Pages (from-to)	1483-1484
Number of pages	2
Journal	American Journal of Transplantation
Volume	23
Issue number	10
DOIs	https://doi.org/10.1016/j.ajt.2023.05.033
State	Published - Oct 2023
Externally published	Yes

Keywords

Transplant
belatacept
costimulation

Access to Document

10.1016/j.ajt.2023.05.033

Cite this

@article{bc3c8719f75e46a3921baa4a6d7d713d,

title = "Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet",

keywords = "Transplant, belatacept, costimulation",

author = "Flavio Vincenti and Klemens Budde and Josep Grinyo and Lionel Rostaing and Kirk, {Allan D.} and Larsen, {Christian P.}",

year = "2023",

month = oct,

doi = "10.1016/j.ajt.2023.05.033",

language = "English",

volume = "23",

pages = "1483--1484",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Elsevier B.V.",

number = "10",

}

TY - JOUR

T1 - Open letter to Bristol Myers Squibb

T2 - Belatacept; we aren't done yet

AU - Vincenti, Flavio

AU - Budde, Klemens

AU - Grinyo, Josep

AU - Rostaing, Lionel

AU - Kirk, Allan D.

AU - Larsen, Christian P.

PY - 2023/10

Y1 - 2023/10

KW - Transplant

KW - belatacept

KW - costimulation

UR - http://www.scopus.com/inward/record.url?scp=85164424038&partnerID=8YFLogxK

U2 - 10.1016/j.ajt.2023.05.033

DO - 10.1016/j.ajt.2023.05.033

M3 - Editorial

C2 - 37394381

AN - SCOPUS:85164424038

SN - 1600-6135

VL - 23

SP - 1483

EP - 1484

JO - American Journal of Transplantation

JF - American Journal of Transplantation

IS - 10

ER -

Open letter to Bristol Myers Squibb: Belatacept; we aren't done yet

Keywords

Access to Document

Fingerprint

Cite this